GCIA
MRTX

Gabelli & Co Investment Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-219,513
Closed -$12.9M – 300
2023
Q4 		$12.9M Buy
+219,513
New +$12.3M 2.42% 12

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gabelli & Co Investment Advisers's MRTX Position: Q1 2024 in Review

Gabelli & Co Investment Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 219,513 shares — an estimated $12.9M sold.

Gabelli & Co Investment Advisers first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $12.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Gabelli & Co Investment Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 219,513 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.9M.
  • Gabelli & Co Investment Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $12.9M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2024, filed 14 May 2024.